Overview

Kannalife Sciences, Inc. (“Kannalife”), is a pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). Further, Kannalife has developed its own patented molecules lead by KLS-13019 called by TIME Magazine/SI as a “super-CBD” and was recently awarded U.S. Patent #9611213, “Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy et al.”. Kannalife is currently conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, to treat Hepatic Encephalopathy (“HE”), Chronic Traumatic Encephalopathy (“CTE”) and Chemotherapy Induced Peripheral Neuropathy ("CIPN"). <iframe width="560" height="315" src="https://www.youtube.com/embed/LWLbe9m4JWo" frameborder="0" allow="autoplay; encrypted-media" allowfullscreen></iframe>